Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Total Valuation
Kymera Therapeutics has a market cap or net worth of $3.16B. The enterprise value is $2.99B.
Market Cap$3.16B
Enterprise Value$2.99B
Share Statistics
Kymera Therapeutics has 65,119,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,119,570
Owned by Insiders19.98%
Owned by Institutions0.75%
Financial Efficiency
Kymera Therapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -28.33%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.33%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee226.31K
Profits Per Employee-1.08M
Employee Count208
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kymera Therapeutics is -13.49. Kymera Therapeutics’s PEG ratio is 0.95.
PE Ratio-13.49
PS Ratio0.00
PB Ratio3.76
Price to Fair Value3.61
Price to FCF-10.82
Price to Operating Cash Flow-14.45
PEG Ratio0.95
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of 47.07M and earned -223.86M in profits. Earnings per share was -2.98.
Revenue47.07M
Gross Profit47.07M
Operating Income-261.63M
Pretax Income-223.86M
Net Income-223.86M
EBITDA-216.24M
Earnings Per Share (EPS)-2.98
Cash Flow
In the last 12 months, operating cash flow was -234.06M and capital expenditures -5.90M, giving a free cash flow of -239.96M billion.
Operating Cash Flow-234.06M
Free Cash Flow-239.96M
Free Cash Flow per Share-3.68
Dividends & Yields
Kymera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.61
52-Week Price Change39.37%
50-Day Moving Average31.63
200-Day Moving Average39.53
Relative Strength Index (RSI)77.83
Average Volume (3m)952.74K
Important Dates
Kymera Therapeutics upcoming earnings date is Aug 1, 2025, TBA Not Confirmed.
Last Earnings DateMay 9, 2025
Next Earnings DateAug 1, 2025
Ex-Dividend Date―
Financial Position
Kymera Therapeutics as a current ratio of 7.53, with Debt / Equity ratio of 21.44%
Current Ratio7.53
Quick Ratio7.53
Debt to Market Cap<0.01
Net Debt to EBITDA0.15
Interest Coverage Ratio-1.05K
Taxes
In the past 12 months, Kymera Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kymera Therapeutics EV to EBITDA ratio is -13.81, with an EV/FCF ratio of -14.40.
EV to Sales63.45
EV to EBITDA-13.81
EV to Free Cash Flow-14.40
EV to Operating Cash Flow-15.35
Balance Sheet
Kymera Therapeutics has $463.15M in cash and marketable securities with $86.33M in debt, giving a net cash position of -$376.82M billion.
Cash & Marketable Securities$463.15M
Total Debt$86.33M
Net Cash-$376.82M
Net Cash Per Share-$5.79
Tangible Book Value Per Share$11.14
Margins
Gross margin is 100.00%, with operating margin of -555.82%, and net profit margin of -475.57%.
Gross Margin100.00%
Operating Margin-555.82%
Pretax Margin-475.57%
Net Profit Margin-475.57%
EBITDA Margin-459.37%
EBIT Margin-475.04%
Analyst Forecast
The average price target for Kymera Therapeutics is $60.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$60.50
Price Target Upside24.49% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast-25.85%
EPS Growth Forecast-23.89%